IMMUNITYBIO, INC. Cash and Restricted Cash
IMMUNITYBIO, INC. (IBRX) had Cash and Restricted Cash of $15.49 million as of 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-11-07
- 2018-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.49M.
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.30M.
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.38M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $24.05M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-09-30 | $15.49M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $16.30M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $11.38M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $24.05M 10-Q · filed 2018-11-07 |
| 2017-09-30 | $21.10M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $39.22M 10-Q · filed 2018-08-06 |
| 2017-03-31 | $13.78M 10-Q · filed 2018-05-07 |
| 2016-12-31 | $8.26M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |